

Chief Development Officer **Peter Wijngaard, PhD**



Peter Wijngaard joined The Medicines Company in February 2011 and has been Chief Development Officer since January 2018, leading the company's ORION clinical development program and medical affairs teams. Peter has extensive experience in the areas of global project leadership, business development, medical affairs, and pharmaceutical marketing. He also has published extensively in the area of transplant immunology and immunosuppression, with an emphasis on the use of mycophenolate mofetil (CellCept®).

Prior to joining The Medicines Company, Peter led European Medical Affairs and Development at ViroPharma Inc, and has held various positions at Hoffmann-La Roche, including International Medical Manager and Lifecycle Leader for the transplantation portfolio, as well as Global Alliance Director managing the Genentech alliance. Peter also was a member of the Roche Organ Transplant Research Foundation Board. Peter served on the Board of Directors of Isotechnika Pharmaceuticals Inc, Aurinia Pharmaceuticals Inc and Ciclofilin Pharmaceuticals Inc. Peter has a PhD in Transplantation Immunology from Utrecht University, the Netherlands.
